US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

18.90

-0.0200-0.11%

Post-market: 18.900.00000.00%19:30 EDT

Volume:653.64K

Turnover:12.43M

Market Cap:871.75M

PE:85.91

High:19.32

Open:19.06

Low:18.80

Close:18.92

52wk High:60.86

52wk Low:9.25

Shares:46.12M

Float Shares:28.59M

Volume Ratio:0.86

T/O Rate:2.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2200

EPS(LYR):1.80

ROE:5.10%

ROA:-0.48%

PB:3.58

PE(LYR):10.50

Loading ...

Overview Company News Filings

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

Press Release: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Oddity Tech faces shareholder class action over alleged digital ad cost misstatements

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Oddity Tech (ODD) Is Down 8.5% After Class Action Over Ad Cost Disclosures - What's Changed

Simply Wall St.

A Look At Oddity Tech (ODD) Valuation After Class Action Lawsuit On Advertising Disclosures

Simply Wall St.

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Oddity price target lowered to $14 from $18 at Jefferies

Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Oddity Tech faces shareholder class action over alleged advertising cost disclosure omissions

Radiopharm Theranostics Reports Business Update

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep

The West Australian

Oddity Tech faces securities class action over alleged misleading ad efficiency disclosures

A Look At Oddity Tech (ODD) Valuation As Securities Class Action Raises Questions On Customer Acquisition Costs

Simply Wall St.

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/ODD/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ODD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":18.9,"timestamp":1790971200000,"preClose":18.92,"halted":0,"volume":653638,"hourTrading":{"tag":"盘后","latestPrice":18.9,"preClose":18.9,"latestTime":"19:30 EDT","volume":14896,"amount":281534.28,"timestamp":1790983804248,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0010570824524314547,"floatShares":28586000,"shares":46124600,"eps":0.22,"marketStatus":"Market Closed","change":-0.02,"latestTime":"10-02 16:00:00 EDT","open":19.06,"high":19.32,"low":18.8,"amount":12430675.05165,"amplitude":0.027484,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.22,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":18.92,"preHourTrading":{"tag":"盘前","latestPrice":19.09,"preClose":18.92,"latestTime":"09:29 EDT","volume":2201,"amount":41865.295834000004,"timestamp":1790947799999,"change":0.17,"changeRate":0.008985,"amplitude":0.054968},"postHourTrading":{"tag":"盘后","latestPrice":18.9,"preClose":18.9,"latestTime":"19:30 EDT","volume":14896,"amount":281534.28,"timestamp":1790983804248,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8565063177297043,"impliedVol":0.8609,"impliedVolPercentile":0.3904},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","floatShares":28586000,"roa":"-0.48%","roe":"5.10%","lyrEps":1.8,"volumeRatio":0.8565063177297043,"shares":46124600,"dividePrice":0,"high":19.32,"amplitude":0.027484,"preClose":18.92,"low":18.8,"week52Low":9.2501,"pbRate":"3.58","psRate":"1.28","week52High":60.855,"institutionHeld":0,"latestPrice":18.9,"eps":0.22,"divideRate":0,"volume":653638,"delay":0,"ttmEps":0.22,"open":19.06,"prevYearClose":40.18,"prevWeekClose":18.64,"prevMonthClose":18.66,"prevQuarterClose":18.66,"fiveDayClose":18.64,"twentyDayClose":14.13,"sixtyDayClose":17.33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODD\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"ODD","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2026/06","expectedEps":0,"defaultRemindTime":1788940800000,"name":null,"time":"Pre-MKt","dateTimestamp":1788926400000,"actualEps":null},{"market":"US","date":"2026-06-02","symbol":"ODD","fiscalQuarterEnding":"2026/03","expectedEps":-0.08,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1780372800000,"reportTimeType":"pre","actualEps":-0.29},{"market":"US","date":"2026-02-25","symbol":"ODD","fiscalQuarterEnding":"2025/12","expectedEps":0.04,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771995600000,"reportTimeType":"pre","actualEps":0.1},{"market":"US","date":"2025-11-19","symbol":"ODD","fiscalQuarterEnding":"2025/09","expectedEps":0.24,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763528400000,"reportTimeType":"post","actualEps":0.28},{"market":"US","date":"2025-08-04","symbol":"ODD","fiscalQuarterEnding":"2025/06","expectedEps":0.79,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754280000000,"reportTimeType":"post","actualEps":0.76}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.7273,"sell":0.2727,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.7273,"analysts":11,"updateTime":1790049600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ODD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ODD","date":"2026-10-02","current":85.909091,"percent":0.983607,"low":6.104615,"twenty":18.837198,"median":26.918593,"eighty":37.95404,"high":144.174884,"avg":29.448448,"sd":16.907133,"marketCap":872676561},"quantilePoints":[{"date":"2023-07-21","current":130.121737,"twenty":124.979326,"median":126.90773,"eighty":128.836134,"marketCap":2827285100},{"date":"2023-07-28","current":127.857619,"twenty":126.192061,"median":128.560276,"eighty":129.606455,"marketCap":2778090339},{"date":"2023-08-04","current":144.174884,"twenty":128.138682,"median":130.121737,"eighty":138.668132,"marketCap":3132631890},{"date":"2023-08-11","current":59.921033,"twenty":128.138682,"median":131.59899,"eighty":138.150305,"marketCap":3096718967},{"date":"2023-08-18","current":49.805463,"twenty":52.028567,"median":129.262933,"eighty":135.506534,"marketCap":2573946329},{"date":"2023-08-25","current":45.155781,"twenty":48.598524,"median":91.807378,"eighty":132.13135,"marketCap":2333650744},{"date":"2023-09-01","current":45.716381,"twenty":47.266275,"median":50.709145,"eighty":131.711973,"marketCap":2362622552},{"date":"2023-09-08","current":40.286255,"twenty":46.134083,"median":49.805463,"eighty":131.410685,"marketCap":2081993665},{"date":"2023-09-15","current":40.648996,"twenty":43.649855,"median":48.206104,"eighty":130.121737,"marketCap":2100740129},{"date":"2023-09-22","current":30.701094,"twenty":40.692965,"median":47.574055,"eighty":129.262933,"marketCap":1586632553},{"date":"2023-09-29","current":31.151773,"twenty":36.878686,"median":46.562777,"eighty":127.857619,"marketCap":1609923614},{"date":"2023-10-06","current":28.491671,"twenty":32.503808,"median":45.749357,"eighty":123.693723,"marketCap":1472449544},{"date":"2023-10-13","current":31.976185,"twenty":32.503808,"median":44.402818,"eighty":59.921033,"marketCap":1652529215},{"date":"2023-10-20","current":29.832714,"twenty":31.459553,"median":41.803173,"eighty":57.306257,"marketCap":1541754654},{"date":"2023-10-27","current":29.832714,"twenty":31.15617,"median":40.714949,"eighty":54.667412,"marketCap":1541754654},{"date":"2023-11-03","current":29.678824,"twenty":30.355941,"median":40.467625,"eighty":50.479578,"marketCap":1533801609},{"date":"2023-11-10","current":30.298177,"twenty":30.305454,"median":36.878686,"eighty":50.003322,"marketCap":1598562121},{"date":"2023-11-17","current":37.221321,"twenty":30.355941,"median":36.411519,"eighty":49.783479,"marketCap":1963834134},{"date":"2023-11-24","current":37.016749,"twenty":30.445709,"median":37.119035,"eighty":49.462508,"marketCap":1953040715},{"date":"2023-12-01","current":36.693741,"twenty":30.5941,"median":37.016749,"eighty":48.26876,"marketCap":1935998475},{"date":"2023-12-08","current":40.591374,"twenty":30.734071,"median":37.17287,"eighty":48.041138,"marketCap":2141641505},{"date":"2023-12-15","current":46.060981,"twenty":30.923136,"median":37.910406,"eighty":47.753992,"marketCap":2430223438},{"date":"2023-12-22","current":50.712301,"twenty":31.153971,"median":38.59949,"eighty":48.041138,"marketCap":2675631695},{"date":"2023-12-29","current":50.884572,"twenty":31.160567,"median":38.868664,"eighty":49.761494,"marketCap":2684720890},{"date":"2024-01-05","current":46.7716,"twenty":31.28148,"median":39.765881,"eighty":49.183424,"marketCap":2467716366},{"date":"2024-01-12","current":46.965405,"twenty":31.46395,"median":40.526773,"eighty":48.323896,"marketCap":2477941710},{"date":"2024-01-19","current":45.899477,"twenty":31.472743,"median":40.645209,"eighty":48.306372,"marketCap":2421702318},{"date":"2024-01-26","current":45.684138,"twenty":31.580467,"median":40.703957,"eighty":48.306372,"marketCap":2410340824},{"date":"2024-02-02","current":45.156558,"twenty":31.989432,"median":42.12028,"eighty":48.252127,"marketCap":2382505165},{"date":"2024-02-09","current":48.246671,"twenty":32.113484,"median":43.346019,"eighty":48.217673,"marketCap":2545542596},{"date":"2024-02-16","current":46.125583,"twenty":32.418946,"median":44.467474,"eighty":48.217673,"marketCap":2433631886},{"date":"2024-02-23","current":42.389454,"twenty":32.503808,"median":43.451996,"eighty":48.101679,"marketCap":2236509975},{"date":"2024-03-01","current":45.414965,"twenty":32.586249,"median":43.346019,"eighty":47.880595,"marketCap":2396138958},{"date":"2024-03-08","current":42.187798,"twenty":32.646706,"median":43.451996,"eighty":47.880595,"marketCap":2469420590},{"date":"2024-03-15","current":43.718187,"twenty":32.976471,"median":43.684021,"eighty":47.798976,"marketCap":2559000375},{"date":"2024-03-22","current":43.038127,"twenty":33.910804,"median":43.451996,"eighty":47.751391,"marketCap":2519193702},{"date":"2024-03-28","current":41.755726,"twenty":34.121582,"median":43.229275,"eighty":47.682483,"marketCap":2444129691},{"date":"2024-04-05","current":35.33401,"twenty":34.429566,"median":43.074483,"eighty":47.592295,"marketCap":2068240969},{"date":"2024-04-12","current":35.168853,"twenty":35.003425,"median":42.938568,"eighty":47.491972,"marketCap":2058573635},{"date":"2024-04-19","current":32.672059,"twenty":33.859301,"median":42.736957,"eighty":47.44561,"marketCap":1912426280},{"date":"2024-04-26","current":30.816464,"twenty":32.666988,"median":42.389454,"eighty":47.239294,"marketCap":1803810931},{"date":"2024-05-03","current":32.701204,"twenty":32.521826,"median":42.280345,"eighty":47.139393,"marketCap":1914132280},{"date":"2024-05-10","current":30.051334,"twenty":32.188614,"median":42.12028,"eighty":47.109682,"marketCap":2161502316},{"date":"2024-05-17","current":34.470881,"twenty":32.029175,"median":41.880975,"eighty":47.036466,"marketCap":2479387030},{"date":"2024-05-24","current":28.991908,"twenty":31.962852,"median":41.668069,"eighty":46.979437,"marketCap":2085300972},{"date":"2024-05-31","current":28.39104,"twenty":31.618936,"median":40.692965,"eighty":46.967038,"marketCap":2042082299},{"date":"2024-06-07","current":35.032218,"twenty":31.466148,"median":40.618291,"eighty":46.952485,"marketCap":2519762369},{"date":"2024-06-14","current":31.434913,"twenty":31.466148,"median":40.526773,"eighty":46.846969,"marketCap":2261018998},{"date":"2024-06-21","current":31.17401,"twenty":31.40776,"median":40.286255,"eighty":46.77806,"marketCap":2242252995},{"date":"2024-06-28","current":31.039605,"twenty":31.15617,"median":39.116208,"eighty":46.676851,"marketCap":2232585660},{"date":"2024-07-05","current":32.549682,"twenty":31.153971,"median":38.825596,"eighty":46.51104,"marketCap":2341201009},{"date":"2024-07-12","current":33.300768,"twenty":31.165014,"median":38.233414,"eighty":46.411983,"marketCap":2395224351},{"date":"2024-07-19","current":31.719535,"twenty":31.193823,"median":37.851188,"eighty":46.379683,"marketCap":2281491001},{"date":"2024-07-26","current":32.889648,"twenty":31.177172,"median":37.124419,"eighty":46.315081,"marketCap":2365653680},{"date":"2024-08-02","current":30.43083,"twenty":31.177172,"median":37.016749,"eighty":46.269497,"marketCap":2188798320},{"date":"2024-08-09","current":24.621128,"twenty":31.077829,"median":36.878686,"eighty":46.15167,"marketCap":2152403648},{"date":"2024-08-16","current":25.909103,"twenty":30.914687,"median":36.319047,"eighty":46.132383,"marketCap":2264999665},{"date":"2024-08-23","current":24.744722,"twenty":30.826367,"median":35.664326,"eighty":46.112663,"marketCap":2163208317},{"date":"2024-08-30","current":23.938111,"twenty":30.576415,"median":35.479654,"eighty":46.043754,"marketCap":2092693640},{"date":"2024-09-06","current":21.999645,"twenty":30.415298,"median":35.251431,"eighty":45.974846,"marketCap":1923230948},{"date":"2024-09-13","current":22.858294,"twenty":30.138302,"median":35.032218,"eighty":45.974846,"marketCap":1998294959},{"date":"2024-09-20","current":23.144511,"twenty":29.832714,"median":34.577614,"eighty":45.899477,"marketCap":2023316296},{"date":"2024-09-27","current":25.837549,"twenty":29.733784,"median":34.493388,"eighty":45.749357,"marketCap":2258744331},{"date":"2024-10-04","current":26.907033,"twenty":29.206161,"median":34.203986,"eighty":45.716381,"marketCap":2352239691},{"date":"2024-10-11","current":26.632604,"twenty":28.857503,"median":34.05976,"eighty":45.700078,"marketCap":2328248903},{"date":"2024-10-18","current":26.737148,"twenty":28.675661,"median":33.782046,"eighty":45.684138,"marketCap":2337388251},{"date":"2024-10-25","current":24.829219,"twenty":28.39104,"median":33.498422,"eighty":45.587236,"marketCap":2170595150},{"date":"2024-11-01","current":24.874957,"twenty":27.774359,"median":33.138619,"eighty":45.414965,"marketCap":2174593614},{"date":"2024-11-08","current":25.903059,"twenty":26.907033,"median":32.701204,"eighty":45.328829,"marketCap":2624135294},{"date":"2024-11-15","current":22.412856,"twenty":26.554196,"median":32.64481,"eighty":45.156558,"marketCap":2270556768},{"date":"2024-11-22","current":25.688798,"twenty":26.266873,"median":32.549682,"eighty":45.155781,"marketCap":2602429343},{"date":"2024-11-29","current":26.196259,"twenty":26.231703,"median":32.526331,"eighty":45.078881,"marketCap":2653838175},{"date":"2024-12-06","current":27.019473,"twenty":26.102043,"median":32.510933,"eighty":44.930453,"marketCap":2737234726},{"date":"2024-12-13","current":27.882156,"twenty":26.129486,"median":32.397731,"eighty":44.829243,"marketCap":2824629741},{"date":"2024-12-20","current":24.673876,"twenty":26.102043,"median":32.284642,"eighty":44.80743,"marketCap":2499611678},{"date":"2024-12-27","current":24.555468,"twenty":26.074468,"median":32.122117,"eighty":44.68052,"marketCap":2487616283},{"date":"2025-01-03","current":24.036731,"twenty":26.028044,"median":31.982415,"eighty":44.572573,"marketCap":2435065032},{"date":"2025-01-10","current":24.916329,"twenty":25.91918,"median":31.969518,"eighty":44.533395,"marketCap":2524173675},{"date":"2025-01-17","current":25.299744,"twenty":25.850651,"median":31.948814,"eighty":44.510542,"marketCap":2563015904},{"date":"2025-01-24","current":24.983991,"twenty":25.688798,"median":31.719535,"eighty":44.467474,"marketCap":2531028186},{"date":"2025-01-31","current":26.906704,"twenty":25.660605,"median":31.631647,"eighty":44.252135,"marketCap":2725810541},{"date":"2025-02-07","current":24.025454,"twenty":25.660605,"median":31.600943,"eighty":44.067933,"marketCap":2433922614},{"date":"2025-02-14","current":24.245353,"twenty":25.528357,"median":31.476041,"eighty":43.718187,"marketCap":2456199775},{"date":"2025-02-21","current":24.809199,"twenty":25.393274,"median":31.447233,"eighty":43.663521,"marketCap":2513320700},{"date":"2025-02-28","current":26.194867,"twenty":25.287339,"median":31.363758,"eighty":43.611255,"marketCap":2658543217},{"date":"2025-03-07","current":24.561126,"twenty":25.149762,"median":31.267028,"eighty":43.481918,"marketCap":2492733193},{"date":"2025-03-14","current":25.259729,"twenty":25.127573,"median":31.17401,"eighty":43.282433,"marketCap":2563635122},{"date":"2025-03-21","current":23.829518,"twenty":25.089994,"median":31.105558,"eighty":43.231428,"marketCap":2418481566},{"date":"2025-03-28","current":23.620487,"twenty":25.062794,"median":30.968449,"eighty":43.177394,"marketCap":2397266815},{"date":"2025-04-04","current":20.886583,"twenty":24.97973,"median":30.909153,"eighty":43.121556,"marketCap":2119800209},{"date":"2025-04-11","current":22.872376,"twenty":24.935811,"median":30.865977,"eighty":43.052669,"marketCap":2321340339},{"date":"2025-04-17","current":23.075906,"twenty":24.876099,"median":30.80242,"eighty":42.991494,"marketCap":2341996807},{"date":"2025-04-25","current":24.341093,"twenty":24.812177,"median":30.590011,"eighty":42.947303,"marketCap":2470401876},{"date":"2025-05-02","current":33.211688,"twenty":24.800183,"median":30.612672,"eighty":42.912727,"marketCap":3531697688},{"date":"2025-05-09","current":37.275211,"twenty":24.812177,"median":30.809442,"eighty":42.852836,"marketCap":3963808661},{"date":"2025-05-16","current":33.075187,"twenty":24.823197,"median":30.881482,"eighty":42.719469,"marketCap":3517182333},{"date":"2025-05-23","current":36.009954,"twenty":24.840888,"median":30.917059,"eighty":42.57047,"marketCap":3829262479},{"date":"2025-05-30","current":37.968215,"twenty":24.859184,"median":31.004027,"eighty":42.466444,"marketCap":4037502005},{"date":"2025-06-06","current":40.472479,"twenty":24.875718,"median":31.151773,"eighty":42.376534,"marketCap":4303802953},{"date":"2025-06-13","current":38.84497,"twenty":24.888137,"median":31.181916,"eighty":42.353632,"marketCap":4130735251},{"date":"2025-06-20","current":36.618957,"twenty":24.907308,"median":31.267028,"eighty":42.321149,"marketCap":3894023297},{"date":"2025-06-27","current":37.637463,"twenty":24.9212,"median":31.363758,"eighty":42.207431,"marketCap":4002330181},{"date":"2025-07-03","current":39.798375,"twenty":24.940682,"median":31.434913,"eighty":42.187798,"marketCap":4232119427},{"date":"2025-07-11","current":38.424967,"twenty":24.946182,"median":31.476041,"eighty":42.12028,"marketCap":4086072618},{"date":"2025-07-18","current":37.17546,"twenty":24.957184,"median":31.58513,"eighty":42.056896,"marketCap":3953201285},{"date":"2025-07-25","current":36.450956,"twenty":24.962685,"median":31.617964,"eighty":41.958776,"marketCap":3876158244},{"date":"2025-08-01","current":36.786958,"twenty":24.983991,"median":31.719535,"eighty":41.803173,"marketCap":3911888350},{"date":"2025-08-08","current":29.269388,"twenty":24.988656,"median":31.680004,"eighty":41.755726,"marketCap":3223525522},{"date":"2025-08-15","current":29.576073,"twenty":25.039696,"median":31.613107,"eighty":41.668069,"marketCap":3257301638},{"date":"2025-08-22","current":30.491058,"twenty":25.068568,"median":31.584654,"eighty":40.714949,"marketCap":3358071703},{"date":"2025-08-29","current":30.947283,"twenty":25.079845,"median":31.470545,"eighty":40.692965,"marketCap":3408317165},{"date":"2025-09-05","current":31.494754,"twenty":25.083205,"median":31.459553,"eighty":40.65779,"marketCap":3468611719},{"date":"2025-09-12","current":31.935772,"twenty":25.085195,"median":31.488146,"eighty":40.645966,"marketCap":3517182333},{"date":"2025-09-19","current":31.793835,"twenty":25.089994,"median":31.584179,"eighty":40.616226,"marketCap":3501550411},{"date":"2025-09-26","current":29.994279,"twenty":25.105422,"median":31.49222,"eighty":40.594895,"marketCap":3303359978},{"date":"2025-10-03","current":30.739447,"twenty":25.114201,"median":31.481537,"eighty":40.590201,"marketCap":3385427566},{"date":"2025-10-10","current":26.927161,"twenty":25.127573,"median":31.451808,"eighty":40.571566,"marketCap":2965569012},{"date":"2025-10-17","current":26.01968,"twenty":25.135101,"median":31.389658,"eighty":40.56278,"marketCap":2865625373},{"date":"2025-10-24","current":24.575011,"twenty":25.135101,"median":31.29655,"eighty":40.533764,"marketCap":2706519695},{"date":"2025-10-31","current":22.697464,"twenty":25.089994,"median":31.260978,"eighty":40.483338,"marketCap":2499739752},{"date":"2025-11-07","current":20.840778,"twenty":25.062794,"median":31.168388,"eighty":40.3235,"marketCap":2295257365},{"date":"2025-11-14","current":21.127625,"twenty":24.961585,"median":31.125566,"eighty":40.286255,"marketCap":2326848745},{"date":"2025-11-21","current":20.632506,"twenty":24.914074,"median":31.026394,"eighty":40.195833,"marketCap":2272856204},{"date":"2025-11-28","current":22.556538,"twenty":24.864441,"median":30.973992,"eighty":40.067661,"marketCap":2484805645},{"date":"2025-12-05","current":23.453377,"twenty":24.800183,"median":30.947283,"eighty":39.942199,"marketCap":2583600507},{"date":"2025-12-12","current":23.171811,"twenty":24.744189,"median":30.91898,"eighty":39.889726,"marketCap":2552583516},{"date":"2025-12-19","current":22.108118,"twenty":24.698354,"median":30.913106,"eighty":39.830715,"marketCap":2435408215},{"date":"2025-12-26","current":21.97255,"twenty":24.603474,"median":30.881482,"eighty":39.790815,"marketCap":2420474108},{"date":"2026-01-02","current":20.950571,"twenty":24.5566,"median":30.865977,"eighty":39.747975,"marketCap":2307893917},{"date":"2026-01-09","current":20.079803,"twenty":24.511489,"median":30.793745,"eighty":39.569474,"marketCap":2211970999},{"date":"2026-01-16","current":18.426908,"twenty":24.453976,"median":30.739447,"eighty":39.33668,"marketCap":2029889771},{"date":"2026-01-23","current":18.270483,"twenty":24.345533,"median":30.673548,"eighty":39.245507,"marketCap":2012658109},{"date":"2026-01-30","current":17.535284,"twenty":24.313015,"median":30.590011,"eighty":39.075971,"marketCap":1931669298},{"date":"2026-02-06","current":15.001193,"twenty":24.204717,"median":30.513869,"eighty":38.986908,"marketCap":1652516376},{"date":"2026-02-13","current":14.396348,"twenty":24.048695,"median":30.485989,"eighty":38.976221,"marketCap":1585887283},{"date":"2026-02-20","current":15.950173,"twenty":23.978855,"median":30.423064,"eighty":38.890175,"marketCap":1757055125},{"date":"2026-02-27","current":7.139339,"twenty":23.850132,"median":30.333914,"eighty":38.866509,"marketCap":790646086},{"date":"2026-03-06","current":7.224918,"twenty":23.762072,"median":30.274296,"eighty":38.85757,"marketCap":800123500},{"date":"2026-03-13","current":6.950028,"twenty":23.706908,"median":30.138302,"eighty":38.84707,"marketCap":769680898},{"date":"2026-03-20","current":7.187922,"twenty":23.614586,"median":30.055287,"eighty":38.79877,"marketCap":796026424},{"date":"2026-03-27","current":6.865617,"twenty":23.526973,"median":29.994279,"eighty":38.783466,"marketCap":760332712},{"date":"2026-04-02","current":6.855385,"twenty":23.427349,"median":29.832714,"eighty":38.753843,"marketCap":759199579},{"date":"2026-04-10","current":7.072813,"twenty":23.171299,"median":29.799737,"eighty":38.548868,"marketCap":783278670},{"date":"2026-04-17","current":7.668822,"twenty":23.13114,"median":29.705337,"eighty":38.419858,"marketCap":849283708},{"date":"2026-04-24","current":7.92462,"twenty":22.959771,"median":29.615359,"eighty":38.380611,"marketCap":877612050},{"date":"2026-05-01","current":7.326053,"twenty":22.880081,"median":29.470231,"eighty":38.282735,"marketCap":811323729},{"date":"2026-05-08","current":7.617663,"twenty":22.847068,"median":29.327683,"eighty":38.184209,"marketCap":843618039},{"date":"2026-05-15","current":6.415412,"twenty":22.722307,"median":29.206161,"eighty":38.041491,"marketCap":710474829},{"date":"2026-05-22","current":6.338673,"twenty":22.581017,"median":28.928656,"eighty":37.95404,"marketCap":701976327},{"date":"2026-05-29","current":6.701906,"twenty":22.463575,"median":28.85355,"eighty":37.93304,"marketCap":742202573},{"date":"2026-06-05","current":11.066918,"twenty":22.355552,"median":28.723098,"eighty":37.913591,"marketCap":570532817},{"date":"2026-06-12","current":12.045027,"twenty":22.082048,"median":28.568928,"eighty":37.870529,"marketCap":620957267},{"date":"2026-06-18","current":12.056017,"twenty":22.028863,"median":28.441356,"eighty":37.806965,"marketCap":621523834},{"date":"2026-06-26","current":14.440844,"twenty":21.88078,"median":28.164079,"eighty":37.786268,"marketCap":744468840},{"date":"2026-07-02","current":18.69397,"twenty":21.779625,"median":28.062977,"eighty":37.763464,"marketCap":963730211},{"date":"2026-07-10","current":19.045649,"twenty":21.529345,"median":27.910348,"eighty":37.653213,"marketCap":981860351},{"date":"2026-07-17","current":14.619425,"twenty":21.127625,"median":27.658443,"eighty":37.642713,"marketCap":753675212},{"date":"2026-07-24","current":13.894717,"twenty":20.840778,"median":27.290118,"eighty":37.637463,"marketCap":716314323},{"date":"2026-07-31","current":13.102906,"twenty":20.627222,"median":27.097913,"eighty":37.608063,"marketCap":675494093},{"date":"2026-08-07","current":12.096366,"twenty":20.299418,"median":26.927161,"eighty":37.545851,"marketCap":623603970},{"date":"2026-08-14","current":11.926373,"twenty":19.78552,"median":26.9103,"eighty":37.435797,"marketCap":614840304},{"date":"2026-08-21","current":11.192718,"twenty":19.351603,"median":26.903692,"eighty":37.382312,"marketCap":577018170},{"date":"2026-08-28","current":13.411578,"twenty":19.023056,"median":26.740169,"eighty":37.366561,"marketCap":691407064},{"date":"2026-09-04","current":12.642134,"twenty":18.467579,"median":26.645529,"eighty":37.293061,"marketCap":651739948},{"date":"2026-09-11","current":48.71712,"twenty":18.466536,"median":26.697683,"eighty":37.389662,"marketCap":738454109},{"date":"2026-09-18","current":58.637034,"twenty":18.468622,"median":26.765743,"eighty":37.639563,"marketCap":888820155},{"date":"2026-09-25","current":54.985532,"twenty":18.603831,"median":26.906704,"eighty":37.799467,"marketCap":833470690},{"date":"2026-10-02","current":57.572012,"twenty":18.837198,"median":26.918593,"eighty":37.95404,"marketCap":872676561}],"updateTime":1791106498973},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ODD\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634219035","title":"PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219035","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634219035?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587200,"startTime":"0","endTime":"0","summary":"Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew England Journal of Medicine published first-in-human reza","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292786/0/en/PMV-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","IE0009354923.USD","BK4139","PMVP","ORR","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634138492","title":"Press Release: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634138492","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634138492?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:05","pubTimestamp":1778583900,"startTime":"0","endTime":"0","summary":"-- U.S. Food and Drug Administration  review of oxylanthanum carbonate.  New Drug Application  resubmission remains on track, with a. Prescription Drug User Fee Act  target action date of June 29,\"As we approach the June 29th PDUFA target action date, we remain optimistic about the potential approval of OLC and focused on preparations for the subsequent launch of OLC,\" said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. \"Our ongoing dialogue with the FDA during the review cycle has been constructive and timely. Uncontrolled hyperphosphatemia remains a significant health concern, affecting nearly 75% of U.S. patients with chronic kidney disease who are undergoing dialysis. OLC has the potential to improve adherence and phosphorus control with reduced pill burden, compared with currently available phosphate binders.\". a bioequivalence study in healthy volunteers, and a tolerability study in. patients with CKD on dialysis), multiple preclinical studies, and. continues to stren","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","IE00B1BXHZ80.USD","LU2746668461.USD","LU2237443382.USD","BK4585","LU0149725797.USD","IE00BHPRN162.USD","LU2237443549.SGD","CMC","IE00BFXG1179.USD","LU2237443895.HKD","BK4604","03160","BK4006","BK4539","LU2237443622.USD","LU2237443978.SGD","BK4555","UNCY","LU0267386448.USD","IE00BZ1G4Q59.USD","TM","IE0009354923.USD","IE00BKVL7J92.USD","LU2746668974.SGD","LU0170899867.USD","LABU","LU2237443465.HKD","BK4588","LU0971096721.USD","ODD","BK4139","LU1363072403.SGD","LU0882574139.USD","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633140669","title":"Oddity Tech faces shareholder class action over alleged digital ad cost misstatements","url":"https://stock-news.laohu8.com/highlight/detail?id=2633140669","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633140669?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:04","pubTimestamp":1778159081,"startTime":"0","endTime":"0","summary":"Class action filed for shareholders who bought Oddity Tech securities between Feb. 26, 2025 and Feb. 24, 2026, alleging misstatements tied to customer acquisition costs and digital ad performance.Shares fell USD 14.28, or 49.21%, to USD 14.74 on Feb. 25, 2026 following disclosure of a severe disruption in digital advertising operations.Complaint alleges an algorithm change at its largest advertising partner pushed ads into lower-quality auctions, driving higher costs and weaker performance, while guidance was raised through three consecutive quarters.SG&A, including advertising, rose to USD 158.18 million in Q1 2025 from USD 117.13 million in Q1 2024, cited as evidence of escalating acquisition costs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL3JpRTv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4183","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914226","title":"Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914226","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914226?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:30","pubTimestamp":1778157000,"startTime":"0","endTime":"0","summary":"– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome  – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290007/0/en/Quoin-Pharmaceuticals-Provides-Corporate-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","BK4183","ODD","QNRX","BK4139","IND","IE0009354923.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633591711","title":"Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2633591711","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633591711?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:02","pubTimestamp":1778097720,"startTime":"0","endTime":"0","summary":"Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3289308/0/en/Revolution-Medicines-Reports-First-Quarter-2026-Financial-Results-and-Update-on-Corporate-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","LU2357305700.SGD","BK4588","LU0456854461.SGD","LU1720051108.HKD","LU1861220033.SGD","PFS","RVMD","LU1978683503.SGD","BK4213","LU1720051017.SGD","BK4139","BK4211","LU2360107325.USD","LU0124384867.USD","LU0348723411.USD","LU1854104046.USD","IE00BD6J9T35.USD","CRC","IE00BFMHRM44.USD","IE0009354923.USD","BMS","LU1861215975.USD","EMA","LU1548497426.USD","LU2298322129.HKD","ODD","BK4195","LU1854103824.USD","ON","BK4081","BK4183","BK4097","LU0724618433.USD","BK4141","IE00BZ199S13.USD","LU1861219969.SGD","BK4585","LU0266512127.USD","PRGS","BK4512","BK4605","LU1861214812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632767570","title":"Oddity Tech (ODD) Is Down 8.5% After Class Action Over Ad Cost Disclosures - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2632767570","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632767570?lang=en_us&edition=fundamental","pubTime":"2026-05-02 21:40","pubTimestamp":1777729231,"startTime":"0","endTime":"0","summary":"The Gross Law Firm recently announced a class action lawsuit on behalf of Oddity Tech shareholders, alleging the company made materially false and misleading statements about digital advertising costs after an algorithm change by its largest advertising partner increased customer acquisition costs and hurt its business outlook.\nThis legal challenge raises fresh questions about how dependent Oddity’s business model is on a single digital ad ecosystem and the transparency of its cost...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/oddity-tech-odd-is-down-85-after-class-action-over-ad-cost-d","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/oddity-tech-odd-is-down-85-after-class-action-over-ad-cost-d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4551","ARTY","BK4183","CHAT","IE0009354923.USD","BK4528","BK4588","AI","BK4543","AIYY","BK4585","BK4587","AGIX","BK4023","ODD","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632661534","title":"A Look At Oddity Tech (ODD) Valuation After Class Action Lawsuit On Advertising Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2632661534","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632661534?lang=en_us&edition=fundamental","pubTime":"2026-05-01 17:41","pubTimestamp":1777628490,"startTime":"0","endTime":"0","summary":"Class action lawsuit puts Oddity Tech (NasdaqGM:ODD) disclosures in focus\nA recent notice from The Gross Law Firm about a class action lawsuit against Oddity Tech (NasdaqGM:ODD) alleges misleading statements around digital advertising costs after an algorithm change by its largest advertising partner.\nSee our latest analysis for Oddity Tech.\nThe class action headlines arrive after a sharp reset in sentiment, with a 1 year total shareholder return of about 78% decline and a 90 day share price...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/a-look-at-oddity-tech-odd-valuation-after-class-action-lawsu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/a-look-at-oddity-tech-odd-valuation-after-class-action-lawsu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AGIX","CHAT","BK4551","BK4588","BK4023","BK4183","IE0009354923.USD","BK4587","AIYY","AIPO","BK4528","BK4543","ARTY","BK4585","ODD","AI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631637932","title":"Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631637932","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631637932?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:30","pubTimestamp":1777552200,"startTime":"0","endTime":"0","summary":"FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to stand","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284867/0/en/Cadrenal-Therapeutics-Announces-End-of-Phase-2-Meeting-with-the-FDA-and-Pivotal-Phase-3-Registration-Path-for-CAD-1005-in-Heparin-Induced-Thrombocytopenia-HIT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4173","BK4585","BK4539","BK4139","IE0009354923.USD","LABU","LENZ","BK4183","BK4588","BK4007","HIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631580707","title":"Oddity price target lowered to $14 from $18 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2631580707","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631580707?lang=en_us&edition=fundamental","pubTime":"2026-04-29 03:10","pubTimestamp":1777403419,"startTime":"0","endTime":"0","summary":"Jefferies lowered the firm’s price target on Oddity (ODD) to $14 from $18 and keeps a Hold rating on the shares. The firm is reducing estimates fur...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oddity-price-target-lowered-to-14-from-18-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oddity-price-target-lowered-to-14-from-18-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","ODD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630589138","title":"Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2630589138","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630589138?lang=en_us&edition=fundamental","pubTime":"2026-04-28 23:04","pubTimestamp":1777388640,"startTime":"0","endTime":"0","summary":"HONG KONG, April 28, 2026 /PRNewswire/ --Fosun International Limited , together with its subsidiaries , released the Environmental, Social and Governance  Report 2025 . Facing the increasingly severe challenges of global climate change, Fosun released its fourth Climate Information Disclosures Report with reference to Part D  of Appendix C2 \"Environmental, Social and Governance Reporting Code\" of the Main Board Listing Rules of the Hong Kong Stock Exchange, the framework of the Task Force on Climate-Related Financial Disclosures  recommendations and the International Financial Reporting Standards S2 Climate-related Disclosures Requirements .As an industry group rooted in China with a global presence, Fosun always places sustainability at the core of its strategy, responding to the expectations of the times and society through concrete actions. Fosun's sustainable development strategy, \"Create IMPACT\", centers on six long-term strategic directions, which stand for I: Innovation-driven, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/creating-a-sustainable-impact-fosun-international-releases-2025-esg-report-and-climate-information-disclosures-report-302755896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","BFC.AU","BFC","BK4134","BK4211","ESG","III","IE0009354923.USD","BK4183","ODD","BK4139","BK4201","ICCC","BK7141","BK7509","BK7505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393335","title":"Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393335","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630393335?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287600,"startTime":"0","endTime":"0","summary":"Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints;favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281473/0/en/Intellia-Therapeutics-Reports-Positive-Phase-3-Results-in-Hereditary-Angioedema-Marking-a-Global-First-for-In-Vivo-Gene-Editing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205194284.USD","IE00BLDYK493.USD","LU1169590202.USD","IE0034390439.USD","LU1861558580.USD","BK4183","LU0205193047.USD","BK4588","BK4198","BK4585","LU1861559042.SGD","IE00B19Z6F94.USD","BK4556","BK4535","IE00B64QTZ34.USD","ODD","IE0009354923.USD","HAE","NTLA","BK4139","LU0012050646.USD","LU1169589451.USD","LU0106261612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629323338","title":"Oddity Tech faces shareholder class action over alleged advertising cost disclosure omissions","url":"https://stock-news.laohu8.com/highlight/detail?id=2629323338","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629323338?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:02","pubTimestamp":1776949371,"startTime":"0","endTime":"0","summary":"Class action filed on behalf of investors who bought Oddity Tech securities between Feb. 26, 2025 and Feb. 24, 2026.Lawsuit alleges Oddity omitted known disruptions to advertising costs that were eroding its financial model.Complaint cites Item 303 disclosure requirements, alleging filings used generic risk language instead of detailing a specific adverse trend.Oddity shares fell 49.2% to $14.74 on Feb. 25, 2026, a drop of $14.28 per share.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL9cyV4g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ODD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629783311","title":"Radiopharm Theranostics Reports Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2629783311","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629783311?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:00","pubTimestamp":1776942000,"startTime":"0","endTime":"0","summary":"Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI (t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3279721/0/en/Radiopharm-Theranostics-Reports-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4128","BK4183","ODD","BK4213","IE0009354923.USD","RADX","SOC","RAD","BK4139","DSMC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629611037","title":"Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies","url":"https://stock-news.laohu8.com/highlight/detail?id=2629611037","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629611037?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:47","pubTimestamp":1776779220,"startTime":"0","endTime":"0","summary":"NANJING, China, April  21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the first patient has been successfully","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3278105/0/en/Leads-Biolabs-PD-L1-4-1BB-Bispecific-Antibody-Opamtistomig-LBL-024-Enters-Phase-Trial-with-First-Patient-Dosing-in-Gastric-Cancer-Pioneering-Enhanced-Immunotherapy-Combination-Stra.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2041044095.USD","BK4124","LU2023250504.SGD","IE00BGHQF417.EUR","HCC","IE00B2PGVK34.USD","LU0868494617.USD","LU2023250843.SGD","BTC","BK4086","IE00B3CCJ633.GBP","BK4183","PFS","ODD","BK4211","OC","BK4006","CPS","BK4195","LU2298321311.HKD","BK4023","LU2092937221.SGD","LU1917777945.USD","LU1974910355.USD","LU2048586759.USD","IE0009354923.USD","PD","LU2106854487.HKD","LU1169590202.USD","LU1169589451.USD","LU2360108059.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628203704","title":"Medicus Pharma submits ODD application to U.S. FDA for SkinJect","url":"https://stock-news.laohu8.com/highlight/detail?id=2628203704","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628203704?lang=en_us&edition=fundamental","pubTime":"2026-04-17 19:35","pubTimestamp":1776425750,"startTime":"0","endTime":"0","summary":"Medicus Pharma (MDCX) announced the submission of an Orphan Drug Designation, ODD, application to the U.S. Food and Drug Administration for SkinJec...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-odd-application-to-u-s-fda-for-skinject-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-odd-application-to-u-s-fda-for-skinject-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","MDCX","ODD","BK4585","IE0009354923.USD","BK4139","LABU","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628278514","title":"ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep","url":"https://stock-news.laohu8.com/highlight/detail?id=2628278514","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628278514?lang=en_us&edition=fundamental","pubTime":"2026-04-17 06:27","pubTimestamp":1776378463,"startTime":"0","endTime":"0","summary":"The Bulls N’ Bears ASX Runner of the Week is… Bison Resources, which exploded on debut, as punters piled into its prime Nevada gold-silver projects amid ongoing fuel security chaos.","market":"hk","thumbnail":"https://images.thewest.com.au/publication/C-22156398/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22156398/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-bison-genetic-signatures-narryer-immutep-c-22156398","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-bison-genetic-signatures-narryer-immutep-c-22156398","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["GDXU","DULL","GLTR","DUST","ODD","GDXJ","IAUI","IAUM","DBC","SGOL","BK4183","CEF","BK7501","BK7067","BAR","DGP","OUNZ","RING","FGDL","GSS.AU","NYM.AU","GOLY","GDXY","UGL","BK7508","USG","GLDM","BK4535","BK4588","BEGS","IAU","GDX","JNUG","GDXD","XME","IMM.AU","PHYS","IE0009354923.USD","BK7048","GLL","GBUG","JDST","BTGD","BK7095","DZZ","BSR.AU","BK4585","BK7104","AAAU","PICK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627155962","title":"Oddity Tech faces securities class action over alleged misleading ad efficiency disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2627155962","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627155962?lang=en_us&edition=fundamental","pubTime":"2026-04-16 21:06","pubTimestamp":1776344776,"startTime":"0","endTime":"0","summary":"Oddity Tech faces securities class action in U.S. District Court for Southern District of New York over alleged misleading disclosures on digital advertising efficiency.Complaint targets purchases of ODD securities from Feb. 26, 2025 to Feb. 24, 2026.Shares fell USD 14.28 to mark a 49.2% drop following Feb. 25, 2026 disclosure of an algorithm change at largest advertising partner.Management projected Q1 2026 revenue decline of about 30% year over year.Lawsuit alleges violations of Exchange Act Sections 10 and 20 tied to customer acquisition costs and sustainability of advertising model.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL4QQ37d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","ODD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626200142","title":"A Look At Oddity Tech (ODD) Valuation As Securities Class Action Raises Questions On Customer Acquisition Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2626200142","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626200142?lang=en_us&edition=fundamental","pubTime":"2026-04-11 11:27","pubTimestamp":1775878071,"startTime":"0","endTime":"0","summary":"Faruqi & Faruqi, LLP has filed a federal securities class action against Oddity Tech (NasdaqGM:ODD). The suit alleges misleading disclosures about customer acquisition costs after an algorithm change by its largest advertising partner prompted a sharp share-price reaction.\nSee our latest analysis for Oddity Tech.\nAt a latest share price of US$14.53, Oddity Tech has seen a 15.82% 1 month share price return and a 4.83% 7 day share price return, but a 63.17% year to date share price decline and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/a-look-at-oddity-tech-odd-valuation-as-securities-class-acti","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/a-look-at-oddity-tech-odd-valuation-as-securities-class-acti","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4183","IE0009354923.USD","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626484187","title":"Immix Biopharma to Participate in the Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2626484187","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626484187?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:45","pubTimestamp":1775738700,"startTime":"0","endTime":"0","summary":"LOS ANGELES, CA, April  09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced tha","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270986/0/en/Immix-Biopharma-to-Participate-in-the-Jefferies-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0029874061.USD","LU0128526141.USD","BK4581","BK4137","ODD","BK4585","XLV","IE0009354923.USD","HCSG","LABU","BK4183","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626215188","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2626215188","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626215188?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:34","pubTimestamp":1775723640,"startTime":"0","endTime":"0","summary":"NANJING, China, April  09, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that its proprietary PD-L1/4-1BB bispecific antibo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270693/0/en/Leads-Biolabs-Opamtistomig-PD-L1-4-1BB-Bispecific-Antibody-Advances-to-Expansion-Phase-in-First-Line-Biliary-Tract-Cancer-Following-Positive-Safety-and-Preliminary-Efficacy-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF417.EUR","IE00B2PGVK34.USD","LU2023250504.SGD","LU2360108059.USD","LU2092937221.SGD","LU1169590202.USD","BTC","LU2023250843.SGD","BK4183","LU2298321311.HKD","LU2041044095.USD","LU2106854487.HKD","BK4006","HCC","BK4023","ORR","IE0009354923.USD","LU0868494617.USD","LU2048586759.USD","LU1974910355.USD","LU1917777945.USD","BK4086","PD","OC","ODD","IE00B3CCJ633.GBP","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":7,"totalSize":143,"code":"91000000","status":"200"}]}}